Quijano-Rubio, Alfredo http://orcid.org/0000-0003-1567-9530
Bhuiyan, Aladdin M.
Yang, Huilin
Leung, Isabel
Bello, Elisa http://orcid.org/0000-0001-7695-2567
Ali, Lestat R.
Zhangxu, Kevin http://orcid.org/0000-0002-7477-6691
Perkins, Jilliane http://orcid.org/0000-0002-2555-4961
Chun, Jung-Ho
Wang, Wentao
Lajoie, Marc J.
Ravichandran, Rashmi
Kuo, Yun-Huai
Dougan, Stephanie K. http://orcid.org/0000-0002-2263-363X
Riddell, Stanley R.
Spangler, Jamie B. http://orcid.org/0000-0001-8187-3732
Dougan, Michael
Silva, Daniel-Adriano http://orcid.org/0000-0002-3195-9009
Baker, David http://orcid.org/0000-0001-7896-6217
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01-CA240339-01, R01-CA240339-01, R01-AI 158488-01, 1K08DK114563–01, R01-CA240339-01)
"la Caixa" Foundation (LCF/BQ/AN15/10380003)
National Science Foundation (Graduate Research Fellowship Program Award)
Melanoma Research Alliance
Emerson Collective
Howard Hughes Medical Institute
Washington Research Foundation
Article History
Received: 13 May 2022
Accepted: 18 September 2022
First Online: 31 October 2022
Competing interests
: A.Q.-R., D.-A.S., D.B. and M.J.L. are coinventors in patent application no. PCT/US2019/062198 covering the targeted split proteins described in this work. A.Q.-R., D.-A.S. and D.B. are cofounders and shareholders of Neoleukin Therapeutics, Inc. M.D. and D.B. are scientific advisors of Neoleukin Therapeutics, Inc. The remaining authors declare no competing interests.